ReviewDiscover oncology2025
Charting the landscape and evolution of research on cell death in acute lymphoblastic leukemia: a comprehensive bibliometric analysis (1990-2024).
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe interplay between regulated cell death pathways and Acute Lymphoblastic Leukemia (ALL) pathobiology profoundly influences disease progression and therapeutic responses.
objectiveThis study performs a comprehensive bibliometric analysis to delineate the historical trajectory, current status, and emerging research frontiers concerning cell death in ALL from 1990 to 2024.
methodsThis bibliometric analysis maps global research on cell death in ALL (1990-2024) using 4,111 publications from the Web of Science Core Collection using search terms related to cell death and ALL. VOSviewer and CiteSpace were utilized to analyze publication trends, geographical and institutional distributions, international collaborations, journal and author productivity and impact, co-citation networks (references, authors, journals), and keyword co-occurrence, clusters, and citation bursts.
resultsPublications grew slowly (1990-1992), expanded rapidly (1993-2015, peak in 2015), then moderated. The United States dominated research output (33.69% publications, 68.41 citations/paper) and collaborated strongly with China, Italy, and the UK. The University of Texas System was the most productive institution (153 articles). Blood ranked first in publications (236) and co-citations (3403). Uckun authored the most papers (31), while Pui was the most co-cited author (736 co-citations). Keyword clusters revealed evolving foci: from apoptosis (1990s) to BH3-only proteins (2000s), with current frontiers in ferroptosis, CAR-T cells, and drug resistance. Terwilliger et al.'s review showed the strongest citation burst.
conclusionThis study dilineates the intellectual landscape of cell death research in ALL, highlighting ferroptosis, immunotherapy integration, and resistance mechanisms as critical future directions to improve therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.